Pharmacogenetics of novel oral anticoagulants: a review of identified gene variants & future perspectives (CROSBI ID 252765)
Prilog u časopisu | pregledni rad (znanstveni) | međunarodna recenzija
Podaci o odgovornosti
Ašić, Adna ; Marjanović, Damir ; Mirat, Jure ; Primorac Dragan
engleski
Pharmacogenetics of novel oral anticoagulants: a review of identified gene variants & future perspectives
Novel oral anticoagulants (NOACs) are becoming a therapy of choice in everyday clinical practice after almost 50 years during which warfarin and related coumarin derivatives were used as the main anticoagulants. Advantages of NOACs over standard anticoagulants include their predictable pharmacodynamics and pharmacokinetics, stable plasma concentrations and less drug–drug and food– drug interactions. However, pharmacogenetics has its place in administration of NOACs, as considerable interindividual variations have been detected. In this review, previous findings in pharmacogenetics of dabigatran, rivaroxaban, apixaban and edoxaban are summarized, along with recommendations for studying genes encoding metabolically important enzymes for four selected NOACs. Future directions include identification of clinically relevant SNPs, and change in optimum dosage for patients who are carriers of significant variants.
anticoagulation ; apixaban ; dabigatran ; edoxaban ; novel oral anticoagulants ; pharmacogenetics ; rivaroxaban
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o izdanju
15 (3)
2018.
10.2217/pme-2017-0092
13
objavljeno
1741-0541
1744-828X
10.2217/pme-2017-0092
Povezanost rada
Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje)